SCHEMBL2345008

SCHEMBL2345008

COC(=O)c1cccc2c1N(C)CC(=O)N2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.43
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 2/20 0.39
BRD4 O60885 2/20 0.39
BRD2 P25440 1/20 0.39
NPC1 O15118 1/20 0.39
CYP3A4 P08684 1/20 0.39
GRM5 P41594 1/20 0.39
RAB9A P51151 1/20 0.39
GRM1 Q13255 1/20 0.39
FTO Q9C0B1 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
ROCK2 O75116 1/20 0.39
CSF1R P07333 1/20 0.39
KDR P35968 1/20 0.39
FLT3 P36888 1/20 0.39
GSK3A P49840 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1549056 0.84 MEN1 (0.52) ALOX5MEN1KMT2ABRD4NPC1
SCHEMBL10365346 0.84 PARP1 (0.44) ALOX5MEN1KMT2ATSHRBRD4
SCHEMBL3593117 0.76 CRBN (0.42) MEN1KMT2ABRD4NPC1CYP3A4
SCHEMBL1549303 0.76 PARP1 (0.43) ALOX5MEN1KMT2ATSHRBRD4
SCHEMBL31170855 0.74 CRBN (0.44) MEN1KMT2ABRD4CRBNLMNA
SCHEMBL5362141 0.74 CCNB2 (0.48) ALOX5TSHRDDB1CRBNGSK3B
SCHEMBL13382909 0.74 CRBN (0.40) MEN1KMT2ABRD4NPC1CYP3A4
SCHEMBL3593120 0.73 CRBN (0.42) MEN1KMT2ABRD4NPC1DDB1
SCHEMBL13150917 0.73 CRBN (0.42) MEN1KMT2ABRD4NPC1CYP3A4
SCHEMBL30696906 0.73 KMT2A (0.48) MEN1KMT2ABRD4CRBNGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008292-B2 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2011-08-30 US disclosed
CN-1984906-A Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC (JP) 2007-06-20 CN disclosed
EP-1777225-A1 FUSED BENZAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR Japan Tobacco, Inc. (JP) 2007-04-25 EP disclosed
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY JAPAN TOBACCO INC. (JP) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY TRPV1, TRPV2, TRPA1 ALOX5 1945/4885MEN1 2454/4885KMT2A 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.